Literature DB >> 2437788

Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors.

P J Podrid, S Lampert, T B Graboys, C M Blatt, B Lown.   

Abstract

Aggravation of arrhythmia by antiarrhythmic drugs is a potentially serious complication. In over 1,287 noninvasive drug studies involving 11 antiarrhythmic drugs, arrhythmia aggravation occurred in 117 tests (9%). During 248 electrophysiologic tests, 45 cases (18%) of aggravation occurred. In an attempt to define predictors of this complication, 51 patients with aggravated arrhythmia were compared with 102 patients without this complication. Arrhythmia aggravation was not associated with age, sex, type or extent of heart disease, baseline electrocardiogram, drug-induced changes on electrocardiogram or density of baseline arrhythmia on monitoring or exercise testing. Aggravation with 1 drug did not predict occurrence with another drug of the same class. The only statistically important relation was the type of presenting arrhythmia. Patients with a history of a sustained tachyarrhythmia (ventricular tachycardia or ventricular fibrillation) had a risk of this complication that was 2.5 times greater than that of patients presenting with only nonsustained ventricular tachycardia or ventricular premature beats (p = 0.01). There was also a relation to the presence of left ventricular dysfunction (p = 0.04). For the most part, however, aggravation of arrhythmia is not predictable, and cautious use of antiarrhythmic drugs is essential.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437788     DOI: 10.1016/0002-9149(87)90200-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Variations in potassium concentration modify the inhibitory effect of lorcainide on myocardial Na(+)-K(+)-ATPase activity.

Authors:  A A Almotrefi; N Dzimiri
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  Therapeutic options in the management of life-threatening arrhythmias.

Authors:  J M Herre; J C Griffin
Journal:  West J Med       Date:  1989-07

Review 5.  Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.

Authors:  A Fitton; M T Buckley
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 6.  Proarrhythmia, a serious complication of antiarrhythmic drugs.

Authors:  P J Podrid
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

Review 7.  Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

8.  Effectiveness of ibutilide in cardioversion of persistent atrial fibrillation in patients with dual chamber stimulation.

Authors:  Massimo Santini; Carlo Pignalberi; Renato Ricci; Leonardo Calò; Luca Santini
Journal:  J Interv Card Electrophysiol       Date:  2003-08       Impact factor: 1.900

Review 9.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

10.  Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.

Authors:  Jonathan D Moreno; Pei-Chi Yang; John R Bankston; Eleonora Grandi; Donald M Bers; Robert S Kass; Colleen E Clancy
Journal:  Circ Res       Date:  2013-07-29       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.